ELND 002

Drug Profile

ELND 002

Alternative Names: ELND-002

Latest Information Update: 10 Feb 2012

Price : $50

At a glance

  • Originator Elan Corporation
  • Class Small molecules
  • Mechanism of Action Integrin alpha4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haematological malignancies; Multiple sclerosis

Most Recent Events

  • 03 Jan 2012 Elan Pharmaceuticals completes enrolment in its phase Ib trial for Multiple sclerosis in USA & Canada (NCT01144351)
  • 30 Dec 2011 Discontinued - Phase-I for Multiple sclerosis in Canada (SC)
  • 30 Dec 2011 Discontinued - Phase-I for Multiple sclerosis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top